San Mateo, CA, United States
San Mateo, CA, United States

Time filter

Source Type

The report provides comprehensive information on the therapeutics under development for Ebolavirus Infections (Ebola Hemorrhagic Fever), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ebolavirus Infections (Ebola Hemorrhagic Fever)   and features dormant and discontinued projects. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Complete report on Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H2 2016 addition with 74 market data tables and 16 figures, spread across 273 pages is available at http://www.reportsnreports.com/reports/764567-ebolavirus-infections-ebola-hemorrhagic-fever-pipeline-review-h2-2016.html This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, Investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis Achelios Therapeutics Inc ,Acorda Therapeutics Inc ,Afferent Pharmaceuticals Inc ,Alder Biopharmaceuticals Inc ,Allergan Plc ,Amgen Inc ,Aralez Pharmaceuticals Inc ,Astellas Pharma,Inc,Biofrontera AG ,BioHealthonomics Inc ,Bristol-Myers Squibb Company,Charleston Laboratories Inc ,CoLucid Pharmaceuticals Inc ,Corium International Inc ,Eli Lilly and Company ,Impel NeuroPharma Inc ,InStar Technologies AS ,Klaria Pharma Holding AB ,Medestea Research & Production SpA,Merck & Co Inc ,Mithra Pharmaceuticals SA ,Monosol Rx LLC ,NAL Pharmaceuticals Ltd ,Noxxon Pharma AG ,Otsuka Holdings Co Ltd ,Promius Pharma LLC ,RedHill Biopharma Ltd,Revance Therapeutics Inc ,Shin Nippon Biomedical Laboratories Ltd,Strategic Science & Technologies LLC,Suda Ltd [ Inquire before buying http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=764567 premium report price at US$2000 for a single user PDF license).


News Article | November 30, 2016
Site: www.newsmaker.com.au

The report provides comprehensive information on the therapeutics under development for Cough, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cough   and features dormant and discontinued projects. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Complete report on Cough - Pipeline Review, H2 2016 addition with 38 market data tables and 12 figures, spread across 96 pages is available at http://www.reportsnreports.com/reports/703640-cough-pipeline-review-h2-2016.html This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, Investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis Ax-8, benzonatate, CCP-05, CCP-06, CCP-07, CCP-08, CLAT-313, codeine + guaifenesin, cromolyn sodium,         DWJ-1340, GRC-17536, GSK-2339345, guaifenesin + hydrocodone, guaifenesin ER , JNJ-39729209, lesogaberan, levodropropizine CR, MD-990, MK-7264, NEO-5937, orvepitant maleate, S-1226, Small Molecule to Antagonize TRPA-1 for Pain And Respiratory Disorders, Small Molecules to Agonize CB1 and CB2 for Chronic Cough and Inflammatory Skin Diseases, ST-015, XEND-0501, Afferent Pharmaceuticals, Alitair Pharmaceuticals, Alveonix AG, AstraZeneca Plc, AusBio Ltd, Charleston Laboratories, Conrig Pharma ApS, Daewoong Pharmaceutical Co., GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., GW Pharmaceuticals Plc, Hyundai Pharmaceutical Co., Johnson & Johnson, NeRRe Therapeutics Ltd, Orbis Biosciences Inc, Inquire before buying http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=703640premium report price at US$2000 for a single user PDF license).


News Article | November 25, 2016
Site: marketersmedia.com

The report provides comprehensive information on the therapeutics under development for Pulmonary Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pulmonary Fibrosis and features dormant and discontinued projects. Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Scope - The report provides a snapshot of the global therapeutic landscape of Pulmonary Fibrosis - The report reviews pipeline therapeutics for Pulmonary Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Pulmonary Fibrosis therapeutics and enlists all their major and minor projects - The report assesses Pulmonary Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Pulmonary Fibrosis Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Pulmonary Fibrosis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Pulmonary Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Table of Contents Table of Contents 2 List of Tables 7 List of Figures 9 Introduction 10 Pulmonary Fibrosis Overview 11 Therapeutics Development 12 Pipeline Products for Pulmonary Fibrosis - Overview 12 Pipeline Products for Pulmonary Fibrosis - Comparative Analysis 13 Pulmonary Fibrosis - Therapeutics under Development by Companies 14 Pulmonary Fibrosis - Therapeutics under Investigation by Universities/Institutes 20 Pulmonary Fibrosis - Pipeline Products Glance 21 Clinical Stage Products 21 Early Stage Products 22 Pulmonary Fibrosis - Products under Development by Companies 23 Pulmonary Fibrosis - Products under Investigation by Universities/Institutes 30 Pulmonary Fibrosis - Companies Involved in Therapeutics Development 31 AdAlta Pty Ltd. 31 Advinus Therapeutics Ltd. 32 Aeolus Pharmaceuticals, Inc. 33 Afferent Pharmaceuticals, Inc. 34 AnaMar AB 35 Angion Biomedica Corp. 36 Antitope Limited 37 aTyr Pharma, Inc. 38 Biogen, Inc. 39 Bioneer Corporation 40 BiOrion Technologies B.V. 41 Bristol-Myers Squibb Company 42 Carolus Therapeutics, Inc. 43 Celgene Corporation 44 Chong Kun Dang Pharmaceutical Corp. 45 Clanotech AB 46 Compugen Ltd. 47 …Continued For more information, please visit http://www.wiseguyreports.com


ReportsnReports.com adds "Postherpetic Neuralgia - Pipeline Review, H2 2016" to its store providing an overview of the Postherpetic Neuralgia's therapeutic pipeline with comprehensive information on the therapeutic development for Postherpetic Neuralgia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Postherpetic Neuralgia and special features on late-stage and discontinued projects. Complete report on H2 2016 pipeline review of Postherpetic Neuralgia with 32 market data tables and 15 figures, spread across 98 pages is available at http://www.reportsnreports.com/reports/729116-postherpetic-neuralgia-pipeline-review-h2-2016.html. Postherpetic neuralgia is a complication of shingles, which is caused by the chickenpox (herpes zoster) virus. Signs and symptoms may include pain, sensitivity to light touch, itching and numbness and weakness or paralysis. The predisposing factors include age, people with HIV and Hodgkin's lymphoma. Treatment includes anticonvulsants, antidepressants and opioid painkillers. Postherpetic Neuralgia pipeline therapeutics constitutes close to 23 molecules. which approximately 23 molecules are developed by Companies. The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 7, 3, 7 and 1 respectively. The report outlays comprehensive information on the therapeutics under development for Postherpetic Neuralgia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Postherpetic Neuralgia and features dormant and discontinued projects. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies discussed in this Postherpetic Neuralgia Pipeline Review, H2 2016 report include Aestus Therapeutics, Inc., ContraVir Pharmaceuticals, Inc., Daewoong Pharmaceutical Co., Ltd., Daiichi Sankyo Company, Limited, Immune Pharmaceuticals Inc., Jiangsu Hengrui Medicine Co., Ltd., KPI Therapeutics, Inc., Lpath, Inc., Merck & Co., Inc., Patagonia Pharmaceuticals, LLC, Pfizer Inc., Phosphagenics Limited, Relmada Therapeutics, Inc., Scilex Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd. and Toray Industries, Inc. Order a copy of this report @ http://www.reportsnreports.com/purchase.aspx?name=729116. Drug Profiles mentioned in this research report are (amitriptyline + ketamine hydrochloride), (clonidine hydrochloride + naltrexone hydrochloride), ATX-08001, bupivacaine hydrochloride, C-746, DWP-05195, funapide, FV-100, ketoprofen, lidocaine hydrochloride, lidocaine hydrochloride patch, Lpathomab, mepivacaine hydrochloride, mirogabalin besylate, MK-8291, naltrexone hydrochloride, PATN-02, pregabalin CR, pregabalin SR, REL-1017, TRK-700, U-2902 and zucapsaicin. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Another newly published market research report titled on Pulmonary Fibrosis - Pipeline Review, H2 2016 provides comprehensive information on the therapeutic development for Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development are AdAlta Pty Ltd., Advinus Therapeutics Ltd, Aeolus Pharmaceuticals, Inc., Afferent Pharmaceuticals, Inc., Angion Biomedica Corp., Apellis Pharmaceuticals Inc, Asahi Kasei Pharma Corp., aTyr Pharma, Inc., Biogen Inc, Bioneer Corporation, BiOrion Technologies B.V., Bristol-Myers Squibb Company, Celgene Corporation, Chrysalis Pharma SAS, Clanotech AB, Compugen Ltd., Cynata Therapeutics Limited, Diffusion Pharmaceuticals Inc., Digna Biotech, S.L., Elsalys Biotech SAS, F. Hoffmann-La Roche Ltd., FibroGen, Inc., FibroStatin SL, Galapagos NV, Galectin Therapeutics, Inc., GenKyoTex S.A., GlaxoSmithKline Plc, Global Blood Therapeutics, Inc., GNI Group Ltd., HEC Pharm Co., Ltd., Yuhan Corporation etc. Pulmonary Fibrosis Pipeline market research report of 377 pages is available at http://www.reportsnreports.com/reports/729115-pulmonary-fibrosis-pipeline-review-h2-2016.html. ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. Connect With Us on:


News Article | November 14, 2016
Site: www.prnewswire.co.uk

ReportsnReports.com adds "Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2016" to its store providing comprehensive information on the therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Complete report on H2 2016 pipeline review of Idiopathic Pulmonary Fibrosis with 78 market data tables and 15 figures, spread across 260 pages is available at http://www.reportsnreports.com/reports/743476-idiopathic-pulmonary-fibrosis-pipeline-review-h2-2016.html . Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease characterized by inflammation and scarring of lung tissue and loss of lung function. Symptoms of IPF include dry cough, shortness of breath, especially during or after physical activity, lasting tiredness and weight loss. Risk factors include smoking, environmental exposure, viral infections, family history and abnormal acid reflux. Treatment includes antioxidants, biological response modulators, anti-fibrotic agents and anticoagulants. Companies discussed in this Idiopathic Pulmonary Fibrosis Pipeline Review, H2 2016 report include AdAlta Pty Ltd., Aeolus Pharmaceuticals, Inc., Afferent Pharmaceuticals, Inc., Apellis Pharmaceuticals Inc, ARMO Biosciences, Inc., Asahi Kasei Pharma Corp., Biogen Inc, Bioneer Corporation, BiOrion Technologies B.V., Bristol-Myers Squibb Company, Celgene Corporation, Chrysalis Pharma SAS, Compugen Ltd., Cynata Therapeutics Limited, F. Hoffmann-La Roche Ltd., FibroGen, Inc., FibroStatin SL, Galapagos NV, GenKyoTex S.A., GlaxoSmithKline Plc, Global Blood Therapeutics, Inc., GNI Group Ltd., HEC Pharm Co., Ltd., Histocell S.L., iBio, Inc., Immunomet Therapeutics, Inc., Inventiva, Isarna Therapeutics GmbH, Kadmon Corporation, LLC, Kasiak Research Private Limited, Kolltan Pharmaceuticals, Inc., Kyorin Pharmaceutical Co., Ltd., Lung Therapeutics Inc, Moerae Matrix, Inc., MorphoSys AG, Novartis AG, Nuevolution AB, Pharmaxis Limited, Promedior, Inc., ProMetic Life Sciences Inc., Pulmatrix, Inc., Respira Therapeutics Inc, Ribomic Inc., Saje Pharma, LLC, Samumed LLC, Sanofi Sorrento Therapeutics, Inc., SPR Biosciences LLC, Teva Pharmaceutical Industries Ltd., Therabron Therapeutics, Inc., Vicore Pharma AB and Yuhan Corporation. The Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Idiopathic Pulmonary Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 14, 13, 1, 49 and 8 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 3 molecules, respectively for Idiopathic Pulmonary Fibrosis. Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Another newly published market research report titled Bronchiectasis - Pipeline Review, H2 2016 provides comprehensive information on the therapeutic development for Bronchiectasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bronchiectasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development are Alitair Pharmaceuticals, Inc., Bayer AG, Grifols, S.A., Insmed Incorporated, Kamada Ltd., Polyphor Ltd., Raptor Pharmaceutical Corp., Recipharm AB, Savara Inc. and Vertex Pharmaceuticals Incorporated. Bronchiectasis Pipeline market research report of 84 pages is available at http://www.reportsnreports.com/reports/743455-bronchiectasis-pipeline-review-h2-2016.html . ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. Connect With Us on:


Ford A.P.D.W.,Afferent Pharmaceuticals | Cockayne D.A.,Hoffmann-La Roche
Handbook of Experimental Pharmacology | Year: 2011

The pharmacological concept of specifically targeting purinoceptors (receptors for ATP and related nucleotides) has emerged over the last two decades in the quest for novel, differentiated therapeutics. Investigations from many laboratories have established a prominent role for ATP in the functional regulation of most tissue and organ systems, including the urinary tract, under normal and pathophysiological conditions. In the particular case of the urinary tract,. ATP signaling via P2X1 receptors participates in the efferent control of detrusor smooth muscle excitability, and this function may be heightened in disease and aging. Perhaps of greater interest, ATP also appears to be involved in bladder sensation, operating via activation of P2X3-containing receptors on sensory afferent neurones, both on peripheral terminals within the urinary tract tissues (e.g., ureters, bladder) and on central synapses in the dorsal horn of the spinal cord. Such findings are based on results from classical pharmacological and localization studies in nonhuman and human tissues, gene knockout mice, and studies using recently identified pharmacological antagonists - some of which have progressed as candidate drug molecules. Based on recent advances in this field, it is apparent that the development of selective antagonists for these receptors will occur that could lead to therapies offering better relief of storage, voiding, and sensory symptoms for patients, while minimizing the systemic side effects that curb the clinical effectiveness of current urologie medicines. © 2011 Springer-Verlag Berlin Heidelberg.


Ford A.P.,Afferent Pharmaceuticals
Purinergic Signalling | Year: 2012

Treating pain by inhibiting ATP activation of P2X3-containing receptors heralds an exciting new approach to pain management, and Afferent's program marks the vanguard in a new class of drugs poised to explore this approach to meet the significant unmet needs in pain management. P2X3 receptor subunits are expressed predominately and selectively in so-called C- and Aδ-fiber primary afferent neurons in most tissues and organ systems, including skin, joints, and hollow organs, suggesting a high degree of specificity to the pain sensing system in the human body. P2X3 antagonists block the activation of these fibers by ATP and stand to offer an alternative approach to the management of pain and discomfort. In addition, P2X3 is expressed pre-synaptically at central terminals of C-fiber afferent neurons, where ATP further sensitizes transmission of painful signals. As a result of the selectivity of the expression of P2X3, there is a lower likelihood of adverse effects in the brain, gastrointestinal, or cardiovascular tissues, effects which remain limiting factors for many existing pain therapeutics. In the periphery, ATP (the factor that triggers P2X3 receptor activation) can be released from various cells as a result of tissue inflammation, injury or stress, as well as visceral organ distension, and stimulate these local nociceptors. The P2X3 receptor rationale has aroused a formidable level of investigation producing many reports that clarify the potential role of ATP as a pain mediator, in chronic sensitized states in particular, and has piqued the interest of pharmaceutical companies. P2X receptor-mediated afferent activation has been implicated in inflammatory, visceral, and neuropathic pain states, as well as in airways hyperreactivity, migraine, itch, and cancer pain. It is well appreciated that oftentimes new mechanisms translate poorly from models into clinical efficacy and effectiveness; however, the breadth of activity seen from P2X3 inhibition in models offers a realistic chance that this novel mechanism to inhibit afferent nerve sensitization may find its place in the sun and bring some merciful relief to the torment of persistent discomfort and pain. The development philosophy at Afferent is to conduct proof of concept patient studies and best identify target patient groups that may benefit from this new intervention. © 2011 The Author(s).


Methods for treating cough, chronic cough and urges to cough associated with respiratory diseases with a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of Formula (I): or a pharmaceutically acceptable salt thereof, wherein R^(1 )and R^(2 )are as defined herein.


Methods for treating cough, chronic cough and urges to cough associated with respiratory diseases with a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of Formula (I): or a pharmaceutically acceptable salt thereof, wherein R^(1 )and R^(2 )are as defined herein.


News Article | August 22, 2016
Site: cen.acs.org

Investors are backing several biotech firms created to advance molecules discarded by larger drug companies. Validating the strategy, Merck & Co. has agreed to pay $500 million to acquire one of them: Afferent Pharmaceuticals, which is based on compounds licensed from Roche. Afferent is developing small-molecule drugs targeting the P2X3 receptor for the treatment of neurogenic conditions. Its lead candidate, AF-219, is being evaluated in Phase IIb clinical trials for refractory, chronic cough and in . . .

Loading Afferent Pharmaceuticals collaborators
Loading Afferent Pharmaceuticals collaborators